Fungal infections in the patient with human immunodeficiency virus infection

Clinical Mycology with CD-ROM

Volumn , Issue , 2009, Pages 417-429

  Saccente, Michael ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85095122495     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-5680-5/00019-0     Document Type: Chapter

References (127)

1. Gottlieb M.S., Schroff R., Schanker H.M., et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med 1981, 305:1425.
2. Masur H., Michelis M., Greene J., et al. An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. N Engl J Med 1981, 305:1431.
3. CDC Current trends update on acquired immune deficiency syndrome (AIDS)-United States. MMWR 1982, 31:507.
4. CDC 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992, 41(RR-17).
5. Levitz S.M. Overview of host defenses in fungal infections. Clin Infect Dis 1992, 14(suppl 1):S37.
6. Palella F.J., Delaney K.M., Moorman A.C., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998, 338:853.
7. CDC Guidelines for preventing opportunistic infections among HIV-infected persons-2002: recommendations of the US Public Health Service and the Infectious Diseases Society of America. MMWR 2002, 51(RR-8).
8. Imam N., Carpenter C.C.J., Mayer K.H., et al. Hierarchical pattern of mucosal Candida infections in HIV-seropositive women. Am J Med 1990, 89:142.
9. McCarthy G.M., Mackie I.D., Koval J., et al. Factors associated with increased frequency of HIV-related oral candidiasis. J Oral Pathol Med 1991, 20:332.
10. Schuman P., Capps L., Peng G., et al. Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection: a randomized, double-blind, placebo controlled trial. Ann Intern Med 1997, 126:689.
11. de Repentigny L., Lewandowski D., Jolicoeur P. Immunopathogenesis of oropharyngeal candidiasis in human immunodeficiency virus infection. Clin Microbiol Rev 2004, 17:729.
12. Mercante D.E., Leigh J.E., Lilly E.A., et al. Assessment of the association between HIV viral load and CD4 cell count on the occurrence of oropharyngeal candidiasis in HIV-infected patients. J Acquir Immune Defic Syndr 2006, 42:578.
13. Klein R.S., Harris C.A., Small C., et al. Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome. N Engl J Med 1984, 311:354.
14. Arribas J.R., Hernandez-Albujar S., Gonzalez-Garcia J.J., et al. Impact of protease inhibitor therapy on HIV-related oropharyngeal candidiasis. AIDS 2000, 14:979.
15. Cauda R., Tacconelli E., Tumbarello M., et al. Role of protease inhibitors in preventing recurrent oral candidosis in patients with HIV infection: a prospective case-control study. J Acquir Immune Defic Syndr 1999, 21:20.
16. Pappas P.G., Rex J.H., Sobel J.D., et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004, 38:161.
17. Pons V., Greenspan D., Lozada-Nur F., et al. Oropharyngeal candidiasis in patients with AIDS: randomized comparison of fluconazole versus nystatin oral suspensions. Clin Infect Dis 1997, 24:1204.
18. Koletar S.L., Russell J.A., Fass R.J., Plouffe J.F. Comparison of oral fluconazole and clotrimazole trouches as treatment for oral candidiasis in patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1990, 34:2267.
19. Pons V., Greenspan D., Debruin M., et al. Therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, prospective multicenter study of oral fluconazole versus clotrimazole trouches. J Acquir Immune Defic Syndr 1993, 6:1311.
20. Graybill J.R., Vazquez J., Darouiche R.O., et al. Randomized trial of itraconazole oral solution for oropharyngeal candidiasis in HIV/AIDS patients. Am J Med 1998, 104:33.
21. Vazquez J.A., Skiest D.J., Nieto L., et al. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis 2006, 42:1179.
22. Selik R.M., Starcher E.T., Curran J.W. Opportunistic diseases reported in AIDS patients: frequencies, associations, and trends. AIDS 1987, 1:175.
23. Kaplan J.E., Hanson D., Dworkin M.S., et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000, 30(suppl 1):S5.
24. San-Andres F.J., Rubio R., Castilla J., et al. Incidence of acquired immunodeficiency syndrome-associated opportunistic diseases and the effect of treatment on a cohort of 1115 patients infected with human immunodeficiency virus, 1989-1997. Clin Infect Dis 2003, 36:1177.
25. Detels R., Tarwater P., Phair J.P., et al. Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis. AIDS 2001, 15:347.
26. Mocroft A., Oancea C., van Lunzen J., et al. Decline in esophageal candidiasis and use of antimycotics in European patients with HIV. Am J Gastroenterol 2005, 100:1446.
27. Wilcox C.M. Esophageal disease in the acquired immunodeficiency syndrome: etiology, diagnosis, and management. Am J Med 1992, 92:412.
28. Wilcox C.M., Straub R.F., Alexander L.N., Clark W.S. Etiology of esophageal disease in human immunodeficiency virus-infected patients who fail antifungal therapy. Am J Med 1996, 101:599.
29. Wilcox C.M., Alexander L.N., Clark W.S., Thompson S.E. Fluconazole compared to endoscopy for human immunodeficiency virus-infected patients with esophageal symptoms. Gastroenterology 1996, 110:1803.
30. Bonacini M., Young T., Laine L. The causes of esophageal symptoms in human immunodeficiency virus infection: a prospective study of 110 patients. Arch Intern Med 1991, 151:1567.
31. Wilcox C.M., Darouiche R.O., Laine L., et al. A randomized, double-blind comparison of itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasis. Clin Infect Dis 1997, 176:227.
32. Ally R., Schurmann D., Kreisel W., et al. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 2001, 33:1447.
33. Villanueva A., Gotuzzo E., Arathoon E.G., et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 2002, 113:294.
34. de Wet N., Llanos-Cuentas A., Suleiman J., et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis 2004, 39:842.
35. Krause D.S., Simjee A.E., van Rensburg C., et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis 2004, 39:770.
36. Schuman P., Sobel J.D., Ohmit S.E., et al. Mucosal candidal colonization and candidiasis in women with or at risk for human immunodeficiency virus infection. Clin Infect Dis 1998, 27:1161.
37. Sobel J.D., Brooker D., Stein G.E., et al. Single oral dose fluconazole compared with conventional clotrimazole topical therapy of Candida vaginitis. Am J Obstet Gynecol 1995, 172:1263.
38. CDC Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from the CDC, the National Institutes of Health and the HIV Medicine Association/ Infectious Diseases Society of America. MMWR 2004, 53(RR-15).
39. Hay R.J. Overview of studies of fluconazole in oropharyngeal candidiasis. Rev Infect Dis 1990, 12(suppl 3):S334.
40. Stevens D.A., Greene S.I., Lang O.S. Thrush can be prevented in patients with acquired immunodeficiency syndrome and the acquired immunodeficiency syndrome-related complex: randomized, double-blind, placebo-controlled study of 100-mg oral fluconazole daily. Arch Intern Med 1991, 151:2458.
41. Leen C.L.S., Dunbar E.M., Ellis M.E., Mandal B.K. Once-weekly fluconazole to prevent recurrence of oropharyngeal candidiasis in patients with AIDS and AIDS-related complex: a double-blind placebo-controlled study. J Infect 1990, 21:55.
42. Revankar S.G., Kirkpatrick W.R., McAtee R.K., et al. A randomized trial of continuous or intermittent therapy with fluconazole for oropharyngeal candidiasis in HIV-infected patients: clinical outcomes and development of fluconazole resistance. Am J Med 1998, 105:7.
43. Fichtenbaum C.J., Powderly W.G. Refractory mucosal candidiasis in patients with human immunodeficiency virus infection. Clin Infect Dis 1998, 26:556.
44. Maenza J.R., Keruly J.C., Moore R.D., et al. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients. J Infect Dis 1996, 173:219.
45. Maenza J.R., Merz W.G., Romagnoli M.J., et al. Infection due to fluconazole-resistant Candida in patients with AIDS: prevalence and microbiology. Clin Infect Dis 1997, 24:28.
46. Powderly W.G. Cryptococcal meningitis and AIDS. Clin Infect Dis 1993, 17:837.
47. Powderly W.G., Finkelstein D.M., Feinberg J., et al. A randomized trial comparing fluconazole with clotrimazole trouches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995, 332:700.
48. Pinner R.W., Hajjeh R.A., Powderly W.G. Prospects for preventing cryptococcosis in persons infected with human immunodeficiency virus. Clin Infect Dis 1995, 21(suppl 1):S103.
49. Mirza S.A., Phelan M., Rimland D., et al. The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000. Clin Infect Dis 2003, 36:789.
50. van Elden L.J.R., Walenkamp A.M.E., Lipovsky M.M., et al. Declining number of patients with cryptococcosis in the Netherlands in the era of highly active antiretroviral therapy. AIDS 2000, 14:2787.
51. Dromer F., Mathoulin-Pelissier S., Fontanet A., et al. Epidemiology of HIV-associated cryptococcosis in France (1985-2001): comparison of the pre-and post-HAART eras. AIDS 2004, 18:555.
52. Chuck S.L., Sande M.A. Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome. N Engl J Med 1989, 321:794.
53. Saag M.S., Powderly W.G., Cloud G.A., et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N Engl J Med 1992, 326:83.
54. van der Horst C.M., Saag M.S., Cloud G.A., et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N Engl J Med 1997, 337:15.
55. Clark R.A., Greer D.L., Valainis G.T., Hyslop N.E. Cryptococcus neoformans pulmonary infection in HIV-1-infected patients. J Acquir Immune Defic Syndr 1990, 3:480.
56. Saag M.S., Cloud G.A., Graybill J.R., et al. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. Clin Infect Dis 1999, 28:291.
57. Larsen R.A., Bozzette S.A., Jones B.E., et al. Fluconazole combined with flucytosine for the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1994, 19:741.
58. Sharkey P.K., Graybill J.R., Johnson E.S., et al. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996, 22:315.
59. Leenders A.C.A.P., Reiss P., Portegies P., et al. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS 1997, 11:1463.
60. Baddour L.M., Perfect J.R., Ostrosky-Zeichner L. Successful use of amphotericin B lipid complex in the treatment of cryptococcosis. Clin Infect Dis 2005, 40(suppl 6):S409.
61. Saag M.S., Graybill R.J., Larsen R.A., et al. Practice guidelines for the management of cryptococcal disease. Clin Infect Dis 2000, 30:710.
62. Denning D.W., Armstrong R.W., Lewis B.H., Stevens D.A. Elevated cerebrospinal fluid pressures in patients with cryptococcal meningitis and acquired immunodeficiency syndrome. Am J Med 1991, 91:267.
63. Bozzette S.A., Larsen R.A., Chui J., et al. A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. N Engl J Med 1991, 324:580.
64. Powderly W.G., Saag M.S., Cloud G.A., et al. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. N Engl J Med 1992, 326:793.
65. Vibhagool A., Sungkanuparph S., Mootsikapun P., et al. Discontinuation of secondary prophylaxis for cryptococcal meningitis in human-immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: a prospective, multicenter, randomized trial. Clin Infect Dis 2003, 36:1329.
66. Mussini C., Pezzotti P., Miro J.M., et al. Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational study. Clin Infect Dis 2004, 38:565.
67. Bradsher R.W. Histoplasmosis and blastomycosis. Clin Infect Dis 1992, 22(suppl 2):S102.
68. McKinsey D.S., Spiegel R.A., Hutwagner L., et al. Prospective study of histoplasmosis in patients infected with human immunodeficiency virus: incidence, risk factors, and pathophysiology. Clin Infect Dis 1997, 24:1195.
69. Huang C.T., McGarry T., Cooper S., et al. Disseminated histoplasmosis in the acquired immunodeficiency syndrome: report of five cases from a nonendemic area. Arch Intern Med 1987, 147:1181.
70. Wheat L.J., Connolly-Stringfield P.A., Baker R.L., et al. Disseminated histoplasmosis in the acquired immune deficiency syndrome: clinical findings, diagnosis and treatment, and review of the literature. Medicine (Baltimore) 1990, 69:361.
71. Wheat J., Hafner R., Wulfsohn M., et al. Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1993, 118:610.
72. Hajjeh R.A., Pappas P.G., Henderson H., et al. Multicenter case-control study of risk factors for histoplasmosis in human immunodeficiency virus-infected persons. Clin Infect Dis 2001, 32:1215.
73. Anaissie E., Fainstein V., Samo T., et al. Central nervous system histoplasmosis: an unappreciated complication of the acquired immunodeficiency syndrome. Am J Med 1988, 84:215.
74. Wheat L.J., Batteiger B.E., Sathapatayavongs B. Histoplasma capsulatum infections of the central nervous system: a clinical review. Medicine (Baltimore) 1990, 69:244.
75. Sarosi G.A., Johnson P.C. Disseminated histoplasmosis in patients with human immunodeficiency virus. Clin Infect Dis 1992, 14(suppl 1):S60.
76. Wheat L.J., Slama T.G., Zeckel M.L. Histoplasmosis in the acquired immune deficiency syndrome. Am J Med 1985, 78:203.
77. Wheat L.J. Histoplasmosis: experience during outbreaks in Indianapolis and review of the literature. Medicine (Baltimore) 1997, 76:339.
78. Wheat L.J., Kohler R.B., Tewari R.P. Diagnosis of disseminated histoplasmosis by detection of Histoplasma capsulatum antigen in serum and urine specimens. N Engl J Med 1986, 314:83.
79. Wheat J., Sarosi G., McKinsey D., et al. Practice guidelines for the management of patients with histoplasmosis. Clin Infect Dis 2000, 30:688.
80. Johnson P.C., Wheat L.J., Cloud G.A., et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med 2002, 137:105.
81. Wheat J., Hafner R., Korzun A.H., et al. Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. Am J Med 1995, 98:336.
82. Wheat J., MaWhinney S., Hafner R., et al. Treatment of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome. Am J Med 1997, 103:223.
83. McKinsey D.S., Gupta M.R., Driks M.R., et al. Histoplasmosis in patients with AIDS: efficacy of maintenance amphotericin B therapy. Am J Med 1992, 92:225.
84. Goldman M., Zackin R., Fichtenbaum C.J., et al. Safety of discontinuation of maintenance therapy for disseminated histoplasmosis after immunologic response to antiretroviral therapy. Clin Infect Dis 2004, 38:1485.
85. Ampel N.M., Dols C.L., Galgiani J.N. Coccidioidomycosis during human immunodeficiency virus infection: results of a prospective study in a coccidioidal endemic area. Am J Med 1993, 94:235.
86. Fish D.G., Ampel N.M., Galgiani J.N., et al. Coccidioidomycosis during human immunodeficiency virus infection: a review of 77 patients. Medicine 1990, 69:384.
87. Ampel N.M. Coccidioidomycosis in persons infected with HIV type 1. Clin Infect Dis 2005, 41:1174.
88. Bronnimann D.A., Adam R.D., Galgiani J.N., et al. Coccidioidomycosis in the acquired immunodeficiency syndrome. Ann Intern Med 1987, 106:372.
89. Galgiani J.N., Ampel N.M. Coccidioidomycosis in human immunodeficiency virus-infected patients. J Infect Dis 1990, 162:1165.
90. Singh V.R., Smith D.K., Lawrence J., et al. Coccidioidomycosis in patients infected with human immunodeficiency virus: review of 91 cases at a single institution. Clin Infect Dis 1996, 23:563.
91. Arguinchona H.L., Ampel N.M., Dols C.L., et al. Persistent coccidioidal seropositivity without clinical evidence of active coccidioidomycosis in patients infected with human immunodeficiency virus. Clin Infect Dis 1995, 20:1281.
92. Pappagianis D., Zimmer B.L. Serology of coccidioidomycosis. Clin Microbiol Rev 1990, 3:247.
93. Tucker R.M., Galgiani J.N., Denning D.W., et al. Treatment of coccidioidal meningitis with fluconazole. Rev Infect Dis 1990, 12(suppl 3):S380.
94. Tucker R.M., Denning D.W., Dupont B., Stevens D.A. Itraconazole therapy for chronic coccidioidal meningitis. Ann Intern Med 1990, 112:108.
95. Graybill J.R., Stevens D.A., Galgiani J.N., et al. and the NIAID-Mycosis Study Group. Itraconazole treatment of coccidioidomycosis. Am J Med 1990, 89:282.
96. Galgiani J.N., Catanzaro A., Cloud G.A., et al. Fluconazole therapy for coccidioidal meningitis. Ann Intern Med 1993, 119:28.
97. Catanzaro A., Galgiani J.N., Levine B.E., et al. Fluconazole in the treatment of chronic pulmonary and nonmeningeal disseminated coccidioidomycosis. Am J Med 1995, 98:249.
98. Galgiani J.N., Catanzaro A., Cloud G.A., et al. Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis: a randomized, double-blind trial. Mycosis Study Group. Ann Intern Med 2000, 133:676.
99. Galgiani J.N., Ampel N.M., Catanzaro A., et al. Practice guidelines for the treatment of coccidioidomycosis. Clin Infect Dis 2000, 30:658.
100. Supparatpinyo K., Chiewchanvit S., Hirunsri P., et al. Penicillium marneffei infection in patients infected with human immunodeficiency virus. Clin Infect Dis 1991, 14:871.
101. Supparatpinyo K., Khamwan C., Baosoung V., et al. Disseminated Penicillium marneffei infection in Southeast Asia. Lancet 1994, 344:110.
102. Sirisanthana T., Supparatpinyo K., Perriens J., et al. Amphotericin B and itraconazole for treatment of disseminated Penicillium marneffei infection in human immunodeficiency virus-infected patients. Clin Infect Dis 1998, 26:1107.
103. Supparatpinyo K., Perriens J., Nelson K.E., et al. A controlled trial of itraconazole to prevent relapse of Penicillium marneffei infection in patients infected with the human immunodeficiency virus. N Engl J Med 1998, 339:1739.
104. Schaffner A. Acquired immune deficiency syndrome: is disseminated aspergillosis predictive of underlying cellular immune deficiency? (letter). J Infect Dis 1984, 149:828.
105. Denning D.W., Follansbee S.E., Scolaro M., et al. Pulmonary aspergillosis in the acquired immunodeficiency syndrome. N Engl J Med 1991, 324:654.
106. Minamoto G.Y., Barlam T.F., Vander Els N.J. Invasive aspergillosis in patients with AIDS. Clin Infect Dis 1992, 14:66.
107. Lortholary O., Meyohas M.-C., Dupont B., et al. Invasive aspergillosis in patients with acquired immunodeficiency syndrome: report of 33 cases. Am J Med 1993, 95:177.
108. Denning D.W. Invasive aspergillosis. Clin Infect Dis 1998, 26:781.
109. Khoo S.H., Denning D.W. Invasive aspergillosis in patients with AIDS. Clin Infect Dis 1994, 19(suppl 1):S41.
110. Kemper C.A., Hostetler J.S., Follansbee S.E., et al. Ulcerative and plaque-like tracheobronchitis due to infection with Aspergillus in patients with AIDS. Clin Infect Dis 1993, 17:344.
111. Pappas P.G., Pottage J.C., Powderly W.G., et al. Blastomycosis in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1992, 116:847.
112. Pappas P.G., Threlkeld M.G., Bedsole G.D., et al. Blastomycosis in immunocompromised patients. Medicine (Baltimore) 1993, 72:311.
113. Chapman S.W., Bradsher R.W., Campbell G.D., et al. Practice guidelines for the management of patients with blastomycosis. Clin Infect Dis 2000, 30:679.
114. Dismukes W.E., Bradsher R.W., Cloud G.C., et al. Itraconazole therapy for blastomycosis and histoplasmosis. Am J Med 1992, 93:489.
115. Heller H.M., Fuhrer J. Disseminated sporotrichosis in patients with AIDS: case report and review of the literature. AIDS 1991, 5:1243.
116. Oscherwitz S.L., Rinaldi M.G. Disseminated sporotrichosis in a patient infected with human immunodeficiency virus. Clin Infect Dis 1992, 15:568.
117. Lipstein-Kresch E., Isenberg H.D., Singer C., et al. Disseminated Sporothrix schenckii infection with arthritis in a patient with acquired immunodeficiency syndrome. J Rheumatol 1985, 12:805.
118. Kauffman C.A. Old and new therapies for sporotrichosis. Clin Infect Dis 1995, 21:981.
119. Goldani L.Z., Sugar A.M. Paracoccidioidomycosis and AIDS: an overview. Clin Infect Dis 1995, 21:1275.
120. Piscitelli S.C., Gallicano K.D. Interactions among drugs for HIV and opportunistic infections. N Engl J Med 2001, 344:984.
121. Peiperl L, Coffey S, Bacon O, Volberding P (eds). HIV InSite Knowledge Base.. Accessed November 20 2006. http://hivinsite.ucsf.edu/InSite%3Fpage%3DKB.
122. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents-A Working Group of the Office of AIDS Research Advisory Council. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents.. Accessed December 1 2006. http://aidsinfo.nih.gov.
123. Johnson L.B., Kauffman C.A. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003, 36:630.
124. Boucher H.W., Groll A.H., Chiou C.C., et al. Newer systemic antifungal agents-pharmacokinetics, safety and efficacy. Drugs 1997, 64:2004.
125. Como J.A., Dismukes W.E. Oral azole drugs as systemic antifungal therapy. N Engl J Med 1994, 330:263.
126. McNeil M.M., Ampel N.M. Opportunistic coccidioidomycosis in patients infected with human immunodeficiency virus: prevention isssues and priorities. Clin Infect Dis 1995, 21(suppl 1):S111.
127. McKinsey D.S., Wheat L.J., Cloud G.A., et al. Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: randomized, placebo-controlled, double-blind study. Clin Infect Dis 1999, 28:1049.